Thank you, Sally, and good morning, good afternoon, good evening to all of our shareholders, and welcome to all to ResMed's second quarter fiscal year 2026 earnings call. For this March and the June ...
NanoMosaic, a leader in advanced analytical technologies for cell and gene therapy development and manufacturing, today announced that the FDA's Center for Biologics Evaluation and Research (CBER) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results